180 related articles for article (PubMed ID: 16823921)
21. The development of self-emulsifying oil-in-water emulsion adjuvant and an evaluation of the impact of droplet size on performance.
Shah RR; Dodd S; Schaefer M; Ugozzoli M; Singh M; Otten GR; Amiji MM; O'Hagan DT; Brito LA
J Pharm Sci; 2015 Apr; 104(4):1352-61. PubMed ID: 25600347
[TBL] [Abstract][Full Text] [Related]
22. [Mutagenic activity of some oil adjuvants used in vaccine preparations].
Dominici S; Di Antonio E; Vizzani A; Vivoli P
Boll Ist Sieroter Milan; 1980; 59(3):233-4. PubMed ID: 7459023
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.
Lawrence GW; Saul A; Giddy AJ; Kemp R; Pye D
Vaccine; 1997 Feb; 15(2):176-8. PubMed ID: 9066035
[TBL] [Abstract][Full Text] [Related]
24. Manufacture of Oil-in-Water Emulsion Adjuvants.
Haensler J
Methods Mol Biol; 2017; 1494():165-180. PubMed ID: 27718193
[TBL] [Abstract][Full Text] [Related]
25. Design and selection of vaccine adjuvants: animal models and human trials.
Alving CR
Vaccine; 2002 May; 20 Suppl 3():S56-64. PubMed ID: 12184368
[TBL] [Abstract][Full Text] [Related]
26. Analysis of adipose tissue immune gene expression after vaccination of rainbow trout with adjuvanted bacterins reveals an association with side effects.
Veenstra KA; Wang T; Alnabulsi A; Douglas A; Russell KS; Tubbs L; Arous JB; Secombes CJ
Mol Immunol; 2017 Aug; 88():89-98. PubMed ID: 28622574
[TBL] [Abstract][Full Text] [Related]
27. Liposome-stabilized oil-in-water emulsions as adjuvants: increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen.
Richards RL; Rao M; Vancott TC; Matyas GR; Birx DL; Alving CR
Immunol Cell Biol; 2004 Oct; 82(5):531-8. PubMed ID: 15479439
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Montanide adjuvants, IMS 3012 (Nanoparticle), ISA 206 and ISA 35 (Emulsion based) along with incomplete Freund's adjuvant for hyperimmunization of equines used for production of polyvalent snake antivenom.
Waghmare A; Deopurkar RL; Salvi N; Khadilkar M; Kalolikar M; Gade SK
Vaccine; 2009 Feb; 27(7):1067-72. PubMed ID: 19100805
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant influenza vaccines.
Stuart-Harris CH
Bull World Health Organ; 1969; 41(3):617-21. PubMed ID: 5309486
[TBL] [Abstract][Full Text] [Related]
30. Comparative assessment of humoral immune responses of aluminum hydroxide and oil-emulsion adjuvants in Influenza (H9N2) and Newcastle inactive vaccines to chickens.
Jafari M; Moghaddam Pour M; Taghizadeh M; Masoudi S; Bayat Z
Artif Cells Nanomed Biotechnol; 2017 Feb; 45(1):84-89. PubMed ID: 26757848
[TBL] [Abstract][Full Text] [Related]
31. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques.
Langermans JA; Schmidt A; Vervenne RA; Birkett AJ; Calvo-Calle JM; Hensmann M; Thornton GB; Dubovsky F; Weiler H; Nardin E; Thomas AW
Vaccine; 2005 Sep; 23(41):4935-43. PubMed ID: 15998554
[TBL] [Abstract][Full Text] [Related]
32. Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants.
Iyer V; Cayatte C; Guzman B; Schneider-Ohrum K; Matuszak R; Snell A; Rajani GM; McCarthy MP; Muralidhara B
Hum Vaccin Immunother; 2015; 11(7):1853-64. PubMed ID: 26090563
[TBL] [Abstract][Full Text] [Related]
33. Immunoenhancing effects of Montanide ISA oil-based adjuvants on recombinant coccidia antigen vaccination against Eimeria acervulina infection.
Jang SI; Lillehoj HS; Lee SH; Lee KW; Park MS; Bauchan GR; Lillehoj EP; Bertrand F; Dupuis L; Deville S
Vet Parasitol; 2010 Sep; 172(3-4):221-8. PubMed ID: 20541870
[TBL] [Abstract][Full Text] [Related]
34. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine.
Kuroda Y; Nacionales DC; Akaogi J; Reeves WH; Satoh M
Biomed Pharmacother; 2004 Jun; 58(5):325-37. PubMed ID: 15194169
[TBL] [Abstract][Full Text] [Related]
35. Experience in the United Kingdom with oil adjuvant influenza vaccines.
Perkins FT
Ann Allergy; 1972 May; 30(5):288-91. PubMed ID: 5063341
[No Abstract] [Full Text] [Related]
36. Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review.
van Doorn E; Liu H; Huckriede A; Hak E
Hum Vaccin Immunother; 2016; 12(1):159-69. PubMed ID: 26378866
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of action of mineral oil adjuvants. I. Conditions influencing the in vitro stability of water-in-oil emulsions.
Steinberg P; Norman PS
J Allergy Clin Immunol; 1973 Apr; 51(4):238-44. PubMed ID: 4689140
[No Abstract] [Full Text] [Related]
38. The impact of size on particulate vaccine adjuvants.
Shah RR; O'Hagan DT; Amiji MM; Brito LA
Nanomedicine (Lond); 2014 Dec; 9(17):2671-81. PubMed ID: 25529570
[TBL] [Abstract][Full Text] [Related]
39. Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant.
Hilgers LA; Lejeune G; Nicolas I; Fochesato M; Boon B
Vaccine; 1999 Jan; 17(3):219-28. PubMed ID: 9987157
[TBL] [Abstract][Full Text] [Related]
40. Development of a novel oil-in-water emulsion and evaluation of its potential adjuvant function in a swine influenza vaccine in mice.
Zhang J; Miao J; Han X; Lu Y; Deng B; Lv F; Zhao Y; Ding C; Hou J
BMC Vet Res; 2018 Dec; 14(1):415. PubMed ID: 30577861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
